Yesterday published that publication Describes the health areas that the government intends to address in the fight against cancer and dementia, using the lessons learned and successes from the COVID-19 response.

“We are indebted to the ingenuity of the life sciences in Britain and its pioneers, with the discovery of the Oxford-AstraZeneca vaccine and the seamless collaboration between our scientists, industry, regulators and the NHS who saved millions of lives during the pandemic “Says Prime Minister Prime Boris Johnson.

“We need to make sure this is the norm and use this new way of working to look for life changing breakthroughs against diseases like cancer, dementia and obesity, as we did with COVID.

“So we’re introducing our new Life Sciences Vision to bottle the formula we developed to fight COVID and improve health outcomes for patients across the UK, safeguarding jobs and investment in the process as we do better build up. “

The biology of aging

One of Johnson’s commitments is to study the underlying biology of aging, with the vision aiming to identify common underlying mechanisms that lead to the organ deterioration and failure that characterize the aging process.

“There is an abundance of new literature on mechanisms that are believed to be involved in common aging processes in multiple organs,” write the authors of the paper.

“These include DNA repair, telomere shortening, stem cell regeneration, signals from insulin-like growth factor (IGF), nutritional factors and chronic inflammation.

Molecular pathways involving nicotinamide adenine dinucleotide (NAD) or sirtuins have been well described and there is now an abundance of literature on possible routes and goals that could be used to combat the most inevitable cause of disease in the human population. “

The hope is that through government-industry collaboration, the pathways associated with aging in multiple systems can be identified and used to discover new diagnostic, therapeutic, and medico-technical interventions to address an increasingly aging population.

The new Life Sciences Vision has been approved by some of the UK’s best-known scientists. Professor Bart De Strooper, Director of the UK Dementia Research Institute, called the strategy “an ambitious action plan that demonstrates and is a great motivator for the UK’s leadership in health sciences”. for the UK Dementia Research Institute.

“Seeing dementia at the top of the agenda is very promising when we face this enormous challenge,” he comments.

“At the UK Dementia Research Institute, we make discoveries quickly, and our work drives the pipeline to turn our knowledge into treatments.

“We look forward to working with the government in line with this new strategy to turn these ideas into reality so that together we can be a scientific superpower that saves lives.”

Bigger role in the industry

In addition to aging and dementia, the government’s plan also includes cancer, mental health, obesity, respiratory disease, and vaccines.

Building on the success of the vaccine rollout, the government’s focus will be on creating “an excellent business environment for life science companies – where incentives and structures are aligned to support business growth, innovation and investment.”

“We will create a business-friendly environment where our life science companies can have access to finance to grow, be incentivized to manufacture onshore and market breakthrough products right here in the UK – and not elsewhere – while we do British position as a scientific superpower, ”says Economy Minister Kwasi Kwarteng.

Dr. Mark Downs, Chief Executive of the Royal Society of Biology (RSB), believed the ten year vision provided a much-needed framework that would benefit not only health but also the economy.

“The confirmation of the continued commitment to achieve shared spending of 2.4% of GDP on research is very welcome,” he comments.

“However, to achieve these goals, it will also be critical to recognize the breadth of science that contributes to health, including the entire biological sciences sector.

“The discovery research underpins our ability to understand and respond to challenges such as the current pandemic and should continue to be a core part of UK funding alongside investments in technology and application methods.”